In addition, in lung squamous cell carcinoma, EZH2 inhibition (GSK126 or EPZ-6438) increased the MHCI/II mRNA and protein levels in 2D cell lines and patient-derived neoplasms (containing IFN-γ), remodeled chromatin markers at key sites, and improved the control of anti-PD-1 tumors in both autologous and homologous models [124]. This evidence concerns the gene EZH2 and neoplasm.